- Home
- HRMY vs FCF Comparison
HRMY vs FCF Comparison
Compare HRMY & FCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- FCF
- Stock Information
- Founded
- HRMY 2017
- FCF 1934
- Country
- HRMY United States
- FCF United States
- Employees
- HRMY N/A
- FCF N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- FCF Major Banks
- Sector
- HRMY Health Care
- FCF Finance
- Exchange
- HRMY Nasdaq
- FCF Nasdaq
- Market Cap
- HRMY 2.1B
- FCF 1.8B
- IPO Year
- HRMY 2020
- FCF N/A
- Fundamental
- Price
- HRMY $35.99
- FCF $17.89
- Analyst Decision
- HRMY Strong Buy
- FCF Buy
- Analyst Count
- HRMY 9
- FCF 7
- Target Price
- HRMY $55.33
- FCF $19.00
- AVG Volume (30 Days)
- HRMY 531.4K
- FCF 480.2K
- Earning Date
- HRMY 10-28-2025
- FCF 10-28-2025
- Dividend Yield
- HRMY N/A
- FCF 3.00%
- EPS Growth
- HRMY 58.41
- FCF N/A
- EPS
- HRMY 3.10
- FCF 1.30
- Revenue
- HRMY $772,527,000.00
- FCF $454,628,000.00
- Revenue This Year
- HRMY $20.09
- FCF $17.70
- Revenue Next Year
- HRMY $16.74
- FCF $8.50
- P/E Ratio
- HRMY $11.61
- FCF $13.86
- Revenue Growth
- HRMY 17.74
- FCF N/A
- 52 Week Low
- HRMY $26.47
- FCF $13.54
- 52 Week High
- HRMY $41.61
- FCF $19.96
- Technical
- Relative Strength Index (RSI)
- HRMY 47.09
- FCF 65.54
- Support Level
- HRMY $36.50
- FCF $17.35
- Resistance Level
- HRMY $38.28
- FCF $17.96
- Average True Range (ATR)
- HRMY 0.95
- FCF 0.31
- MACD
- HRMY -0.17
- FCF 0.06
- Stochastic Oscillator
- HRMY 9.84
- FCF 76.83
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.